Three Remain Liable On UK Liothyronine Price Abuse – But Fines Slimmed On Appeal
Advanz Pharma Loses Both Liability And Fine Appeals, Deemed ‘Unimpeachable’
Executive Summary
Advanz Pharma has failed in its appeal against a £40.9m fine imposed by the UK’s Competition and Markets Authority for its historical pricing practices for liothyronine tablets.
You may also be interested in...
UK’s CMA Issues £35m In Fines Over Prochlorperazine
Multiple firms have been fined a total of more than £35m by the UK’s competition regulator in connection with an alleged illegal arrangement connected with anti-nausea drug prochlorperazine that led prices to increase by 700%. But Advanz and Alliance have hit back at the decision, revealing plans to appeal.
UK’s CMA Issues £35m In Fines Over Prochlorperazine
Multiple firms have been fined a total of more than £35m by the UK’s competition regulator in connection with an alleged illegal arrangement connected with anti-nausea drug prochlorperazine that led prices to increase by 700%. But Advanz and Alliance have hit back at the decision, revealing plans to appeal.
Advanz Hits Back Over £100m+ Fines For UK Liothyronine Pricing
Advanz Pharma has immediately hit back at a decision announced by the UK’s competition regulator to impose fines of more than £100m over the firm’s historical pricing of liothyronine tablets.